Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sung Ham

Vascular Surgery Harbor City, CA Medical Doctor

NPI 1790929164 CMS profile 172881

1050 Pacific Coast Hwy Fl 2, Harbor City, CA 90710

Open in the dashboard

General payments

$41,862

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sung Ham of Harbor City, CA is reported in the CMS Open Payments database as having received $41,862 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,033 18
2024 General $1,998 33
2023 General $287 12
2022 General $392 8
2021 General $683 14
2020 General $142 7
2019 General $37,327 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sung Ham
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Sung Ham were reported at $1,033. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Sung Ham Vascular Surgery median Middle half National median
2019 $37,327 $796 $226–$2,363 $163
2020 $142 $348 $118–$1,110 $114
2021 $683 $471 $158–$1,421 $132
2022 $392 $725 $222–$2,183 $149
2023 $287 $836 $257–$2,440 $160
2024 $1,998 $909 $252–$2,619 $164
2025 $1,033 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $39,568 67 payments
  2. Cook Medical LLC $1,024 26 payments
  3. Endologix, Inc. $573 12 payments
  4. Bolton Medical Inc $274 8 payments
  5. Medtronic, Inc. $87 3 payments
  6. Stryker Corporation $66 1 payment
  7. Medtronic Vascular, Inc. $60 1 payment
  8. LeMaitre Vascular, Inc. $56 3 payments
  9. Boston Scientific Corporation $40 1 payment
  10. Silk Road Medical, Inc. $30 1 payment
  11. Other $83 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $28,350 3 payments
  2. Travel and Lodging $7,367 8 payments
  3. Food and Beverage $6,144 116 payments
Products named General payments · program years 2019–2025
  1. EXCLUDER AAA Endoprosthesis $21,959 13 payments
  2. TAG Thoracic Endoprosthesis $14,184 3 payments
  3. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,279 23 payments
  4. GORE EXCLUDER Iliac Branch Endoprosthesis $1,011 14 payments
  5. Ovation $542 10 payments
  6. GORE EXCLUDER AAA Endoprosthesis $472 6 payments
  7. Conformable TAG Thoracic Endoprosthesis $334 6 payments
  8. ZENITH ALPHA $284 2 payments
  9. Cook Medical Thoracic $257 3 payments
  10. Zilver PTX $176 4 payments
  11. Other $1,521 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

315

Median for Vascular Surgery: 122

Drug cost

$59,776

Median for Vascular Surgery: $14,135

Branded share of claims

91.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 42 $47,128
Pradaxa Dabigatran Etexilate Mesylate Brand 36 $9,633
Clopidogrel Clopidogrel Bisulfate Brand 94 $1,749
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 94 $812
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 23 $284
Meloxicam Generic 14 $95
Tramadol Hcl Generic 12 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$7,280

Medicare's payments for the services billed

Medicare patients

22

Average age 65

Services billed

58

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 73%
Heart failure 50%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record